Epstein J, Lozada-Nur F, McLeod WA, Spinelli J; International Conference on AIDS.

Int Conf AIDS. 1989 Jun 4-9; 5: 190 (abstract no. M.B.O.21).

Cancer Control Agency of B.C.; Vancouver, Canada

OBJECTIVE: To observe the efficacy of local intralesional Vinblastine in management of oral Kaposi's sarcoma (KS). METHODS: All patients had histologically proven intraoral KS. Patients with bilateral palatal lesions were selected, one side was treated with intralesional 0.2 to 0.8 mg of Vinblastine (0.2 mg/ml) following local anesthesia. Patients were seen every two weeks following injection. In addition to palatal lesions, lesions affecting the gingiva and tongue were treated using the same technique. RESULTS: 10 patients with bilateral palatal lesions were treated. All were homosexual/bisexual males, demonstrating HIV positivity and meeting the diagnostic criteria of AIDS. Age range - 24 to 56 years (mean 37.6 years). After a single injection with Vinblastine, the mean reduction in tumor size of the palatal lesions was 51%. Meanwhile, increase of the untreated KS occurred in 7 of 10 patients. 4 patients received repeat treatments to the same lesions with an overall reduction in size of 71 %. Combining the results with 1 or 2 injection treatments, the mean reduction in surface area of the palatal lesions was 63 %. Follow-up was a mean of 3.6 months. Discomfort following injection was assessed using visual analogue scales with pain of 24 to 48 hours reported: 2 patients reported no pain, 3 patients mild pain, 4 moderate pain and 1 severe pain. Pain was controlled with oral analgesics. The gingival and tongue lesions showed more complete reduction in size than the palatal lesions treated. CONCLUSION: The use of intralesional Vinblastine appears to provide good palliation of oral KS lesions without significant side-effects due to the treatment.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• HIV Seropositivity
• Humans
• Male
• Pain
• Palatal Neoplasms
• Sarcoma, Kaposi
• Vinblastine
• drug therapy
• methods
• organization & administration

Other ID:

• 00079089

UI: 102176681

From Meeting Abstracts